Influenza results in annual epidemics and global pandemics of acute respiratory illness that increases morbidity, mortality, and hospital admissions. Fortunately, there are currently two classes of antivirals licensed for the treatment of influenza in much of the world: the M2 inhibitiors (amantadine and rimantadine) and the neuraminidase inhibitors (oseltamivir, peramivir and zanamivir). There are also other antivirals licensed in Asia (laninamivir and favipiravir) and Russia (umifenovir). Additionally, a wide range of novel antivirals have been or are being studied in the treatment of influenza.

中文翻译：

---

寻找正确的流感抗病毒组合疗法

流感导致急性呼吸道疾病的年度流行和全球流行，从而增加发病率，死亡率和住院人数。幸运的是，目前在世界许多地方，有两类抗病毒药被许可用于治疗流感：M2抑制剂（金刚烷胺和金刚乙胺）和神经氨酸酶抑制剂（oseltamivir，peramivir和zanamivir）。在亚洲（laninamivir和favipiravir）和俄罗斯（umifenovir）也许可使用其他抗病毒药。另外，已经或正在研究各种新型抗病毒药来治疗流感。